293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1, 1 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) (QC tested).
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase Ⅰ | The First Affiliated Hospital of Nanchang University | Multiple myeloma (MM) | Details | |
| TNB-383B | TNB-383B | Phase Ⅰ | Teneobio, Abbvie | Multiple myeloma (MM) | Details |
| Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) | Phase Ⅰ | Yake Biotechnology | Multiple myeloma (MM) | Details | |
| LCAR-B38M cell product | JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528 | Phase Ⅲ | Nanjing Chuanqi Biotech, Janssen | Multiple myeloma (MM) | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase Ⅰ | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple myeloma (MM) | Details | |
| BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) | IND Filing | Unicar-Therapy Bio-medicine Technology | Multiple myeloma (MM) | Details | |
| Belantamab mafodotin | GSK-2857916 | BLA Filing | GlaxoSmithKline | Multiple myeloma (MM) | Details |
| Idecabtagene vicleucel | bb-2121 | BLA Filing | bluebird bio, Celgene | Multiple myeloma (MM) | Details |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase Ⅱ | General Hospital of the People's Liberation Army | Multiple myeloma (MM) | Details | |
| GC-012F | GC-012F | Phase Ⅰ | Gracell Biotechnology | Multiple myeloma (MM) | Details |
| CC-98633 | CC-98633 | Phase Ⅰ | Celgene | Multiple myeloma (MM) | Details |
| CART-BCMA | CART-BCMA; MTV-273,CART BCMA,MTV273 | Phase Ⅰ | University of Pennsylvania, Novartis | Multiple myeloma (MM) | Details |
| P-BCMA-101 | P-BCMA-101 | Phase Ⅱ | Poseida Therapeutics | Multiple myeloma (MM) | Details |
| BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase Ⅱ | Asclepius Technology Company Group | Multiple myeloma (MM) | Details | |
| BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase Ⅰ | iCell Gene Therapeutics | Multiple myeloma (MM) | Details | |
| Anti-BCMA CAR T-cell therapy (Arcellx) | CART-ddBCMA | Phase Ⅰ | Arcellx | Multiple myeloma (MM) | Details |
| HPN-217 | HPN-217 | Phase Ⅱ | Harpoon Therapeutics, Abbvie | Multiple myeloma (MM) | Details |
| CC-99712 | CC-99712 | Phase Ⅰ | Celgene | Multiple myeloma (MM) | Details |
| Human BCMA chimeric antigen receptor autologous T cell（Nanjing Reindeer Medical Technology） | CT103A | Phase Ⅰ | Innovent Biologics, Nanjing IASO Biotherapeutics | Multiple myeloma (MM) | Details |
| MEDI-2228 | MEDI-2228,MEDI 2228,MEDI2228 | Phase Ⅰ | MedImmune | Multiple myeloma (MM) | Details |
| SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase Ⅰ | Seattle Genetics | Multiple myeloma (MM) | Details |
| PBCAR-269A | PBCAR-269A | Phase Ⅱ | Precision BioSciences | Multiple myeloma (MM) | Details |
| Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Phase Ⅰ | PersonGen Biomedicine, Second Affiliated Hospital of Suzhou UniversitySecond Affiliated Hospital of Suzhou University | Multiple myeloma (MM) | Details | |
| BCMA CAR-T Cells (Pregene) | Phase Ⅰ | Pregene | Multiple myeloma (MM) | Details | |
| bb-21217 | bb-21217,bb 21217,bb21217 | Phase Ⅰ | bluebird bio, Celgene | Multiple myeloma (MM) | Details |
| AMG-420 | AMG-420; BI-836909 | Phase Ⅰ | Micromet, Boehringer Ingelheim, Amgen | Multiple myeloma (MM) | Details |
| CTX-120 | CTX-120 | Phase Ⅰ | CRISPR Therapeutics | Multiple myeloma (MM) | Details |
| KITE-585 | KITE-585,KITE585 | Phase Ⅰ | Kite Pharma, National Cancer Institute | Multiple myeloma (MM) | Details |
| REGN-5459 | REGN-5459 | Phase Ⅱ | Regeneron Pharmaceutical | Multiple myeloma (MM) | Details |
| PF-06863135 | PF-06863135,PF 06863135 | Phase Ⅰ | Pfizer | Multiple myeloma (MM) | Details |
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase Ⅰ | iCell Gene Therapeutics | Multiple myeloma (MM), Lymphoma | Details | |
| LCAR-B4822M | LCAR-B4822M,LCAR B4822M,LCARB4822M | Phase Ⅰ | GenScript Biotech Corporation | Multiple myeloma (MM) | Details |
| CAR-BCMA T cell therapy | CT-053-CARsgen,CT053 | Phase Ⅱ | CARsgen Therapeutics | Multiple myeloma (MM) | Details |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase Ⅰ | Shanghai Hrain Biotechnology | Multiple myeloma (MM) | Details |
| JNJ-64007957 | JNJ-7957; JNJ-64007957; JNJ-64007959 | Phase Ⅰ | Janssen, Genmab | Multiple myeloma (MM) | Details |
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Phase Ⅱ | Chongqing Precision Biotech | Plasma cell neoplasms, Multiple myeloma (MM) | Details | |
| AUTO-2 | AUTO-2; SUB-96123,AUTO 2; SUB 96123 | Phase Ⅱ | Autolus | Multiple myeloma (MM) | Details |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase Ⅱ | Chongqing Precision Biotech | Multiple myeloma (MM) | Details | |
| CC-93269 | CC-93269; EM-901 | Phase Ⅰ | Celgene | Multiple myeloma (MM) | Details |
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase Ⅲ | The First Affiliated Hospital of Soochow University | Multiple myeloma (MM) | Details | |
| ACTR 087/SEA BCMA combination therapy | Phase Ⅰ | Unum Therapeutics, Seattle Genetics | Multiple myeloma (MM) | Details | |
| anti-BCMA CAR T-cell Therapy (Juno Therapeutics) | ET-140; ET140-CAR; JCARH-125; FCARH-143; MCARH-171 | Phase Ⅱ | Juno Therapeutics | Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas | Details |
| ALLO-715 | ALLO-715 | Phase Ⅰ | Allogene Therapeutics, Cellectis | Multiple myeloma (MM) | Details |
| BCBM CAR T cell (Pregene) | Phase Not Specified | Pregene, BioCast | Multiple myeloma (MM) | Details |
This web search service is supported by Google Inc.
A-Z
